Enzon Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	-	0.03	-	0.03	0.7
Revenue Growth (YoY)	-	-	-	-96.29%	1248.08%
Gross Profit	-	0.03	-	0.03	0.7
Selling, General & Admin	1.36	1.35	1.04	1.06	1.17
Operating Expenses	1.36	1.35	1.04	1.06	1.17
Operating Income	-1.36	-1.33	-1.04	-1.03	-0.47
Interest & Investment Income	1.92	2.45	2.26	0.65	0.01
EBT Excluding Unusual Items	0.57	1.13	1.22	-0.39	-0.46
Merger & Restructuring Charges	-3.96	-	-	-	-
Pretax Income	-3.39	1.13	1.22	-0.39	-0.46
Income Tax Expense	0.02	0.35	-0.16	-0.2	0.01
Net Income	-3.41	0.78	1.37	-0.19	-0.47
Preferred Dividends & Other Adjustments	2.12	1.28	1.28	1.28	2.02
Net Income to Common	-5.53	-0.5	0.1	-1.46	-2.49
Net Income Growth	-	-43.34%	-	-	-
Shares Outstanding (Basic)	74	74	74	74	74
Shares Outstanding (Diluted)	74	74	74	74	74
Shares Change (YoY)	-	-	-	-	45.23%
EPS (Basic)	-0.07	-0.01	0.00	-0.02	-0.03
EPS (Diluted)	-0.07	-0.01	0.00	-0.02	-0.03
Gross Margin	-	100.00%	-	100.00%	100.00%
Operating Margin	-	-5103.85%	-	-3969.23%	-66.90%
Profit Margin	-	-1911.54%	-	-5619.23%	-355.49%
EBIT	-1.36	-1.33	-1.04	-1.03	-0.47
EBIT Margin	-	-	-	-	-66.90%
Effective Tax Rate	-	30.84%	-	-	-
Revenue as Reported	-	0.03	-	0.03	0.7

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.